Latest Oncology News

Tilsotolimod Demonstrates Encouraging Activity, Safety in Early-Stage Melanoma

May 23rd 2022

Chris Ryan

The synthetic Toll-like receptor 9 agonist tilsotolimod reduced the sentinel lymph node biopsy positivity rate vs placebo in patients with localized, excised melanoma.

Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23rd 2022

OncLive Staff

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

May 23rd 2022

Sylvester Comprehensive Cancer Center

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

FDA Grants Priority Review to Mirvetuximab Soravtansine for FRα-High, Platinum-Resistant Ovarian Cancer

May 23rd 2022

Caroline Seymour

The FDA has accepted and filed a biologics license application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha–high, platinum-resistant ovarian cancer who have previously received between 1 and 3 systemic therapies.

Tucatinib Plus Trastuzumab Elicits Positive Results in HER2+ Metastatic CRC

May 23rd 2022

Chris Ryan

The combination of tucatinib and trastuzumab produced promising response rates in patients with previously treated HER2-positive metastatic colorectal cancer.

Latest Oncology Videos

Dr. Lee on the Importance of Collaboration in Precision Medicine

Unmet Needs and Future Perspectives in Advanced RCC

Dr. O’Donnell on the Ideal Patients for CAR T-Cell Therapies

Mechanism of Action of Ruxolitinib

Incorporating ctDNA Into Routine Practice: Clinical Pearls

Dr. Feldman on Lenvatinib and Pembrolizumab Plus Chemotherapy in NSCLC

Dr. Ailawadhi on the Examination of Iopofosine I-131 in Waldenström Macroglobulinemia

Dr. Robesti on Optimizing Patient Selection for Salvage Lymph Node Dissection in Prostate Cancer

Dr. Lenz on the European Approval of Liso-cel in Relapsed/Refractory LBCL

Dr. Deol on Collaboration in the Administration of CAR T-cell Therapy

Differentiated Thyroid Cancer: Unmet Needs and Future Directions

Dr. Vail Discusses Emerging Advances in Biomarker Testing in Lung Cancer

Dr. Massarelli Discusses Frontline Immunotherapy in NSCLC

Dr. Harari on Upright Proton Radiation Therapy in Cancer Care

Dr. LoRusso on the Importance of Clinical Trials in MDM2-Amplified Dedifferentiated Liposarcoma

Dr. Blay on the Current Treatment Challenges in Soft Tissue Sarcomas

Patient Profile 1: Trastuzumab Deruxtecan for HER2+ Metastatic BC

Patient Profile 1: 62-Year-Old Woman With Metastatic Breast Cancer

Myelofibrosis: Observation and Triggers to Initiate Therapy

Risk Assessment and Staging of Myelofibrosis

Metastatic CRPC: Clinical Pearls and Practical Advice

Is There a Role for Cabozantinib in the First-Line Setting in Advanced RCC in Certain Populations?

Sequencing Therapies in the Second Line and Beyond in Advanced RCC

All Oncology News

TP53 and IGHV Status Retain Utility as Prognostic Markers in CLL

September 9th 2021

Jessica Hergert

Historical prognostic markers for chemoimmunotherapy have largely lost their clinically relevance in the context of targeted therapies for patients with chronic lymphocytic leukemia; however, IGHV and TP53 mutational status remain important predictive markers of response, now for novel treatments.

Lurbinectedin/Doxorubicin Misses OS End Point in Relapsed SCLC, But Shows Superior Safety Vs SOC

September 9th 2021

Courtney Marabella

The combination of lurbinectedin and doxorubicin produced comparable efficacy to that of standard-of-care vincristine, cyclophosphamide, and doxorubicin or topotecan in patients with relapsed small cell lung cancer, missing the primary end point of the phase 3 ATLANTIS trial.

Noncovalent BTK Inhibitors, CAR T-Cell Therapy Generate Excitement in CLL

September 9th 2021

Caroline Seymour

Sitting at the forefront of clinical development, pirtobrutinib and lisocabtagene maraleucel have generated significant enthusiasm in chronic lymphocytic leukemia.

Controlling Infections Could Be Key to Improving Survival in CLL

September 9th 2021

Jason Harris

Patients with chronic lymphocytic leukemia are at an increased risk for infection whether they are in the premalignant state of monoclonal B lymphocytosis, during active surveillance for those are treatment naïve, or are on active treatment.

Higher Rates of Respiratory Disorders Retrospectively Identified in Polycythemia Vera

September 9th 2021

Tony Berberabe, MPH

Estimated 4-year mortality rates were greater than 10% in patients with polycythemia vera and vascular complications led to approximately one-third of these deaths, according to a retrospective analysis of the prospective REVEAL trial (NCT02252159) presented during the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting.

Adjuvant Atezolizumab Improves DFS in Early-Stage NSCLC Across Most Disease Stages and Prior Therapies

September 9th 2021

Kristi Rosa

Adjuvant atezolizumab improved disease-free survival over best supportive care in patients with PD-L1–positive, stage II to IIIA non–small cell lung cancer, with benefit observed across most subgroups analyzed, according to data from an exploratory analysis of the phase 3 IMpower010 trial.

Lisberg Discusses the Promise of Datapotamab Deruxtecan in Lung Cancer

September 9th 2021

OncLive Staff

Lisberg discusses the excitement with datopotamab deruxtecan in non–small cell lung cancer and previews anticipated data from the NSCLC cohort of the TROPION-PanTumor01 trial at the International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer.

Pirtobrutinib Shows Impressive Efficacy in Previously Treated CLL/SLL

September 9th 2021

Gina Mauro

Pirtobrutinib, showcased promising efficacy signals across dose levels in previously treated patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

KRd-ASCT Improves Long-Term PFS in Multiple Myeloma

September 9th 2021

Jamie Cesanek

The effectiveness of this treatment in patients with multiple myeloma may be an option for a patient population who represent an unmet need.

Treatment Strategies Utilizing New Agents and Existing Therapies Can Improve Outcomes in Myelofibrosis

September 9th 2021

Nichole Tucker

Various phase 2 and 3 studies are currently underway utilizing both new and existing treatments in an effort to improve outcomes for patients with myelofibrosis.

Flexible Approaches Could Help to Increase Lung Cancer Clinical Trial Enrollment During COVID-19 Pandemic

September 9th 2021

Lindsay Fischer

Flexibilities in time and place were effective strategies to mitigate COVID–19-related patient concerns and to increase participation in international lung cancer clinical trials.

Frontline Durvalumab/Chemo, With or Without Tremelimumab, Improves PFS in Advanced NSCLC

September 9th 2021

Gina Mauro

The first-line combination of durvalumab and chemotherapy, with or without tremelimumab, led to a statistically significant improvement in progression-free survival compared with chemotherapy alone in patients with metastatic non–small cell lung cancer, according to data from the phase 3 POSEIDON trial.

Data Confirms Efficacy of Fixed-Volume Isatuximab-Based Combination for Newly Diagnosed Multiple Myeloma

September 9th 2021

Brittany Lovely

The safety and efficacy of the quadruplet regimen of fixed-dose isatuximab-irfcc in combination with bortezomib, lenalidomide, and dexamethasone were confirmed for patients with newly diagnosed multiple myeloma with no immediate intent for transplant.

Future of PV Treatments Centers Around More Tailored Approaches

September 9th 2021

Dylann Cohn-Emery

Future treatment approaches for patients with polycythemia vera (PV) should center around adapting therapy using the available criteria, and eventually finding new targets.

MRD Could Play Role in Predicting Post-ASCT Outcomes in Myeloma

September 9th 2021

Darlene Dobkowski, MA

For patients with myeloma have undergone an autologous stem cell transplant and are currently on maintenance therapy with lenalidomide, minimal residual disease may be a powerful predictor of outcomes.

See All News